{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:32:17Z","timestamp":1788931937858,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22304067"],"award-info":[{"award-number":["22304067"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020KH019"],"award-info":[{"award-number":["ZR2020KH019"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021LSW001"],"award-info":[{"award-number":["ZR2021LSW001"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MB097"],"award-info":[{"award-number":["ZR2021MB097"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MC017"],"award-info":[{"award-number":["ZR2021MC017"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QB196"],"award-info":[{"award-number":["ZR2023QB196"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QB257"],"award-info":[{"award-number":["ZR2023QB257"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2501700"],"award-info":[{"award-number":["2021YFC2501700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jpba.2024.116006","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:44:39Z","timestamp":1706787879000},"page":"116006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Highly drug\/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibody"],"prefix":"10.1016","volume":"241","author":[{"given":"Rongrong","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingcheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fugui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusha","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaizu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116006_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-921-1_1","article-title":"Therapeutic proteins","volume":"899","author":"Dimitrov","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"3","key":"10.1016\/j.jpba.2024.116006_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"17","author":"Shepard","year":"2017","journal-title":"Clin. Med"},{"key":"10.1016\/j.jpba.2024.116006_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/PPA.S235430","article-title":"Analysis of patient preferences in lung cancer - estimating acceptable tradeoffs between treatment benefit and side effects","volume":"14","author":"Janssen","year":"2020","journal-title":"Patient Preference Adherence"},{"issue":"5","key":"10.1016\/j.jpba.2024.116006_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00005-012-0189-7","article-title":"Immunogenicity to biologics: mechanisms, prediction and reduction","volume":"60","author":"Sethu","year":"2012","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.jpba.2024.116006_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000478077","article-title":"The immunogenicity of biologic therapies","volume":"53","author":"Garc\u00eas","year":"2018","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.jpba.2024.116006_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154-155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpba.2024.116006_bib7","unstructured":"FDA, Guidance for Industry. Immunogenicity Testing of Therapeutic Protein Products \u2014 Developing and Validating Assays for Anti-Drug Antibody Detection, 2019."},{"key":"10.1016\/j.jpba.2024.116006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2015.02.006","article-title":"Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins","volume":"419","author":"Hu","year":"2015","journal-title":"J. Immunol. Methods"},{"issue":"6","key":"10.1016\/j.jpba.2024.116006_bib9","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1208\/s12248-017-0148-7","article-title":"Drug target interference in immunogenicity assays: recommendations and mitigation strategies","volume":"19","author":"Zhong","year":"2017","journal-title":"AAPS J."},{"issue":"5","key":"10.1016\/j.jpba.2024.116006_bib10","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-020-00497-2","article-title":"Drug removal strategies in competitive ligand binding neutralizing antibody (NAb) assays: highly drug-tolerant methods and interpreting immunogenicity data","volume":"22","author":"Partridge","year":"2020","journal-title":"AAPS J."},{"issue":"1-2","key":"10.1016\/j.jpba.2024.116006_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2007.07.004","article-title":"An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug","volume":"327","author":"Bourdage","year":"2007","journal-title":"J. Immunol. Methods"},{"issue":"3","key":"10.1016\/j.jpba.2024.116006_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yrtph.2007.07.005","article-title":"Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA","volume":"49","author":"Smith","year":"2007","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1-2","key":"10.1016\/j.jpba.2024.116006_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jim.2005.10.007","article-title":"Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein","volume":"308","author":"Lofgren","year":"2006","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.jpba.2024.116006_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32159-6","article-title":"Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance","volume":"13","author":"Zhuang","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jpba.2024.116006_bib15","article-title":"Targeted therapy for head and neck cancer: signaling pathways and clinical studies","volume":"8","author":"Li","year":"2023","journal-title":"Signal. Transduct. Target Ther."},{"issue":"8","key":"10.1016\/j.jpba.2024.116006_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.jpba.2024.116006_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.annonc.2019.10.007","article-title":"Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives","volume":"31","author":"Martinelli","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jpba.2024.116006_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-62703-327-5_7","article-title":"Erbitux Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry","volume":"988","author":"Janin-Bussat","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.jpba.2024.116006_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-020-04228-4","article-title":"Correlations between serum Erbitux and EGFR-related markers, and skin disorders in head and neck cancer patients","volume":"87","author":"Shibata","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"issue":"6","key":"10.1016\/j.jpba.2024.116006_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100328","article-title":"Management of adverse events from the treatment of encorafenib plus Erbitux for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study","volume":"6","author":"Tabernero","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.jpba.2024.116006_bib21","first-page":"300","article-title":"Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development","volume":"41","author":"Kaur","year":"2021","journal-title":"Biotechnology"},{"issue":"2","key":"10.1016\/j.jpba.2024.116006_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/07388551.2020.1869684","article-title":"Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development","volume":"41","author":"Kaur","year":"2021","journal-title":"Crit. Rev. Biotechnol."},{"issue":"1","key":"10.1016\/j.jpba.2024.116006_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/mabs.3.1.14021","article-title":"Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors","volume":"3","author":"Wang","year":"2011","journal-title":"MABs"},{"issue":"6","key":"10.1016\/j.jpba.2024.116006_bib24","first-page":"1018","article-title":"Characterization of N-glycosylation in an anti-EGFR monoclonal antibody produced by different expression systems","volume":"33","author":"Wang","year":"2017","journal-title":"Sheng Wu Gong Cheng Xue Bao= Chin. J. Biotechnol."},{"issue":"4","key":"10.1016\/j.jpba.2024.116006_bib25","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-023-00830-5","article-title":"Neutralizing antibody validation testing and reporting harmonization","volume":"25","author":"Myler","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2024.116006_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jpba.2016.09.009","article-title":"Development, validation, and application of ELISA for detection of anti-HD105 antibodies in pre-clinical safety evaluation using monkeys","volume":"131","author":"Choi","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116006_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-020-04228-4","article-title":"Correlations between serum Erbitux and EGFR\u2011related markers, and skin disorders in head and neck cancer patients","volume":"87","author":"Shibata","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116006_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/mabs.3.1.14021","article-title":"Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors","volume":"3","author":"Wang","year":"2011","journal-title":"MABs"},{"key":"10.1016\/j.jpba.2024.116006_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40880-019-0374-8","article-title":"CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial","volume":"39","author":"Shi","year":"2019","journal-title":"Cancer Commun."},{"key":"10.1016\/j.jpba.2024.116006_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2020.112896","article-title":"An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics","volume":"487","author":"Coddens","year":"2020","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.jpba.2024.116006_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-023-00841-2","article-title":"Development of a cell-based neutralizing antibody assay for Zinpentraxin Alfa: challenges and mitigation strategies","volume":"25","author":"Yin","year":"2023","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2024.116006_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2023.113484","article-title":"Assay development considerations to improve drug tolerance in direct competitive ligand binding neutralizing antibody assays, pretreatment strategies","volume":"517","author":"Rathi","year":"2023","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.jpba.2024.116006_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-020-00497-2","article-title":"Drug removal strategies in competitive ligand binding neutralizing antibody (NAb) assays: highly drug-tolerant methods and interpreting immunogenicity data","volume":"22","author":"Partridge","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2024.116006_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112642","article-title":"Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody","volume":"474","author":"Wang","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2024.116006_bib35","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1208\/s12248-017-0148-7","article-title":"Drug target interference in immunogenicity assays: recommendations and mitigation strategies","volume":"19","author":"Zhong","year":"2017","journal-title":"AAPS J."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:38:33Z","timestamp":1760002713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"alternative-id":["S0731708524000463"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116006","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly drug\/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibody","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116006"}}